About the Study

For adults with a diagnosis of Major Depressive Disorder (MDD) experiencing an inadequate response to standard antidepressants.

The goal of this study is to evaluate the efficacy, safety, and tolerability of CLE-100, compared to placebo, in improving depressive symptoms in subjects with major depressive disorder.
This study is sponsored by Biohaven Pharmaceuticals Inc.

Length of Study:  4 weeks screening period. 29 days double-blind treatment period. 1 week safety follow-up period.
Total length: About 10 weeks.

Eligibility 

You may be eligible to participate in this study if you:

• are between the ages of 18-65 years old
• meet DSM-5 criteria for Major Depressive Disorder (MDD) diagnosis
• have had an inadequate response to at least 2 antidepressant medications in your current depressive episode
• are currently taking an antidepressant medication for at least 6 weeks at time of screening

If chosen for this study, you will be compensated for every study visit that you complete, and we can provide transportation if needed. 

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.